NYSE:DVA - DaVita Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$68.25 +0.13 (+0.19 %)
(As of 05/21/2018 02:32 PM ET)
Previous Close$68.35
Today's Range$68.05 - $68.70
52-Week Range$52.51 - $80.71
Volume57,746 shs
Average Volume1.55 million shs
Market Capitalization$11.89 billion
P/E Ratio20.58
Dividend YieldN/A
Beta1.1

About DaVita (NYSE:DVA)

DaVita logoDaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure or end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also provides outpatient, hospital inpatient, and home-based hemodialysis services; owns clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers. In addition, the company operates DaVita Rx, a pharmacy that provides oral medications and medication management services to patients with ESRD; disease management services; vascular access services; clinical research programs; physician services; and direct primary care services. As of December 31, 2017, it provided dialysis and administrative services in the United States through a network of 2,510 outpatient dialysis centers serving approximately 197,800 patients; and operated 237 outpatient dialysis centers located in 11 countries outside of the United States. Further, the company provides acute inpatient dialysis services in approximately 900 hospitals and related laboratory services in the United States. The company was formerly known as DaVita HealthCare Partners Inc. and changed its name to DaVita Inc. in September 2016. DaVita Inc. was founded in 1994 and is headquartered in Denver, Colorado.

Receive DVA News and Ratings via Email

Sign-up to receive the latest news and ratings for DVA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Miscellaneous health & allied services, not elsewhere classified
Sub-IndustryHealth Care Services
SectorMedical
SymbolNYSE:DVA
CUSIP23918K10
Phone303-405-2100

Debt

Debt-to-Equity Ratio1.94
Current Ratio2.94
Quick Ratio2.90

Price-To-Earnings

Trailing P/E Ratio20.58
Forward P/E Ratio16.65
P/E Growth0.99

Sales & Book Value

Annual Sales$10.88 billion
Price / Sales1.09
Cash Flow$7.7206 per share
Price / Cash8.84
Book Value$26.66 per share
Price / Book2.56

Profitability

EPS (Most Recent Fiscal Year)$3.32
Net Income$663.61 million
Net Margins2.94%
Return on Equity13.84%
Return on Assets3.61%

Miscellaneous

Employees74,500
Outstanding Shares174,500,000

DaVita (NYSE:DVA) Frequently Asked Questions

What is DaVita's stock symbol?

DaVita trades on the New York Stock Exchange (NYSE) under the ticker symbol "DVA."

How will DaVita's stock buyback program work?

DaVita announced that its board has approved a stock repurchase plan on Wednesday, October 11th 2017, which allows the company to repurchase $1,500,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization allows the company to repurchase shares of its stock through open market purchases. Shares repurchase plans are usually an indication that the company's board believes its shares are undervalued.

How were DaVita's earnings last quarter?

DaVita (NYSE:DVA) posted its quarterly earnings data on Thursday, May, 3rd. The company reported $1.05 EPS for the quarter, beating analysts' consensus estimates of $0.92 by $0.13. The company earned $2.85 billion during the quarter, compared to analyst estimates of $2.79 billion. DaVita had a return on equity of 13.84% and a net margin of 2.94%. The business's revenue for the quarter was up 8.3% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.79 earnings per share. View DaVita's Earnings History.

When is DaVita's next earnings date?

DaVita is scheduled to release their next quarterly earnings announcement on Tuesday, August, 7th 2018. View Earnings Estimates for DaVita.

What price target have analysts set for DVA?

11 Wall Street analysts have issued 1 year price targets for DaVita's stock. Their predictions range from $60.00 to $97.00. On average, they anticipate DaVita's share price to reach $79.00 in the next twelve months. View Analyst Ratings for DaVita.

Who are some of DaVita's key competitors?

Who are DaVita's key executives?

DaVita's management team includes the folowing people:
  • Mr. Kent J. Thiry, Chairman & CEO (Age 62)
  • Mr. James K. Hilger, Chief Accounting Officer (Age 56)
  • Ms. Kathleen Alyce Waters, Chief Legal Officer (Age 50)
  • Mr. Javier J. Rodriguez, Chief Exec. Officer of Kidney Care (Age 47)
  • Ms. LeAnne M. Zumwalt, Group VP of Purchasing & Public Affairs (Age 59)

Has DaVita been receiving favorable news coverage?

Media stories about DVA stock have trended somewhat positive on Monday, Accern Sentiment reports. The research firm rates the sentiment of press coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. DaVita earned a daily sentiment score of 0.15 on Accern's scale. They also gave news stories about the company an impact score of 48.11 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the next few days.

Who are DaVita's major shareholders?

DaVita's stock is owned by many different of institutional and retail investors. Top institutional investors include BlackRock Inc. (7.09%), Manning & Napier Group LLC (2.09%), Dimensional Fund Advisors LP (1.58%), OppenheimerFunds Inc. (1.47%), Northern Trust Corp (1.19%) and Neuberger Berman Group LLC (1.18%). Company insiders that own DaVita stock include Charles Berg, James K Hilger, Javier Rodriguez, Jeanine Marie Jiganti, Kent J Thiry, Leanne M Zumwalt, Michael David Staffieri, Pamela M Arway and William L Roper. View Institutional Ownership Trends for DaVita.

Which major investors are selling DaVita stock?

DVA stock was sold by a variety of institutional investors in the last quarter, including Park West Asset Management LLC, FIL Ltd, Neuberger Berman Group LLC, Manning & Napier Group LLC, DekaBank Deutsche Girozentrale, BlackRock Inc., Prudential Financial Inc. and Sei Investments Co.. Company insiders that have sold DaVita company stock in the last year include Charles Berg, James K Hilger, Javier Rodriguez, Kent J Thiry and Leanne M Zumwalt. View Insider Buying and Selling for DaVita.

Which major investors are buying DaVita stock?

DVA stock was acquired by a variety of institutional investors in the last quarter, including OppenheimerFunds Inc., Boston Partners, Wedge Capital Management L L P NC, Old Mutual Global Investors UK Ltd., Rock Springs Capital Management LP, Pendal Group Ltd, Mackay Shields LLC and Toronto Dominion Bank. View Insider Buying and Selling for DaVita.

How do I buy shares of DaVita?

Shares of DVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is DaVita's stock price today?

One share of DVA stock can currently be purchased for approximately $68.25.

How big of a company is DaVita?

DaVita has a market capitalization of $11.89 billion and generates $10.88 billion in revenue each year. The company earns $663.61 million in net income (profit) each year or $3.32 on an earnings per share basis. DaVita employs 74,500 workers across the globe.

How can I contact DaVita?

DaVita's mailing address is 2000 16TH STREET, DENVER CO, 80202. The company can be reached via phone at 303-405-2100 or via email at [email protected]


MarketBeat Community Rating for DaVita (DVA)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  336 (Vote Outperform)
Underperform Votes:  357 (Vote Underperform)
Total Votes:  693
MarketBeat's community ratings are surveys of what our community members think about DaVita and other stocks. Vote "Outperform" if you believe DVA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DVA will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

DaVita (NYSE:DVA) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
11 Wall Street analysts have issued ratings and price targets for DaVita in the last 12 months. Their average twelve-month price target is $79.00, suggesting that the stock has a possible upside of 15.75%. The high price target for DVA is $97.00 and the low price target for DVA is $60.00. There are currently 1 sell rating, 4 hold ratings, 4 buy ratings and 2 strong buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyHold
Consensus Rating Score: 2.642.642.641.89
Ratings Breakdown: 1 Sell Rating(s)
4 Hold Rating(s)
4 Buy Rating(s)
2 Strong Buy Rating(s)
1 Sell Rating(s)
4 Hold Rating(s)
4 Buy Rating(s)
2 Strong Buy Rating(s)
1 Sell Rating(s)
4 Hold Rating(s)
4 Buy Rating(s)
2 Strong Buy Rating(s)
2 Sell Rating(s)
6 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $79.00$79.00$79.00$63.00
Price Target Upside: 15.75% upside5.86% upside5.86% upside14.57% upside

DaVita (NYSE:DVA) Consensus Price Target History

Price Target History for DaVita (NYSE:DVA)

DaVita (NYSE:DVA) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/14/2018SunTrust BanksReiterated RatingHold$80.00MediumView Rating Details
2/13/2018Robert W. BairdSet Price TargetBuy$97.00HighView Rating Details
1/11/2018Bank of AmericaReiterated RatingBuy$85.00 ➝ $92.00HighView Rating Details
12/11/2017CitigroupUpgradeNeutral ➝ Buy$67.71 ➝ $82.00MediumView Rating Details
12/7/2017JPMorgan ChaseBoost Price TargetOutperform ➝ Strong-Buy$4.90 ➝ $84.00LowView Rating Details
12/7/2017Raymond JamesUpgradeOutperform ➝ Strong-Buy$65.00 ➝ $84.00HighView Rating Details
12/6/2017KeyCorpReiterated RatingHoldLowView Rating Details
11/8/2017Royal Bank of CanadaLower Price TargetSector Perform$64.00 ➝ $60.00N/AView Rating Details
10/23/2017Wolfe ResearchUpgradeMarket Perform ➝ OutperformN/AView Rating Details
8/3/2017Jefferies GroupReiterated RatingHold$70.00MediumView Rating Details
5/25/2017Goldman SachsReiterated RatingSell$62.00HighView Rating Details
11/1/2016Wells FargoReiterated RatingOutperformN/AView Rating Details
(Data available from 5/21/2016 forward)

Earnings

DaVita (NYSE:DVA) Earnings History and Estimates Chart

Earnings by Quarter for DaVita (NYSE:DVA)

DaVita (NYSE:DVA) Earnings Estimates

2018 EPS Consensus Estimate: $4.02
2019 EPS Consensus Estimate: $4.56
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20182$0.88$0.93$0.91
Q2 20182$0.98$1.04$1.01
Q3 20182$1.03$1.04$1.04
Q4 20182$1.01$1.12$1.07
Q1 20192$1.04$1.06$1.05
Q2 20192$1.14$1.15$1.15
Q3 20192$1.17$1.17$1.17
Q4 20192$1.16$1.22$1.19

DaVita (NYSE DVA) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
7/30/2018$0.98N/AView Earnings Details
5/3/2018Q1 2018$0.92$1.05$2.7883 billion$2.8494 billionViewN/AView Earnings Details
2/13/2018Q4 2017$0.94$0.92$3.8959 billion$2.7809 billionViewListenView Earnings Details
11/7/2017Q3 2017$0.94$0.81$3.9076 billion$3.9228 billionViewN/AView Earnings Details
8/1/2017Q2 2017$0.90$0.92$3.8170 billion$3.8775 billionViewListenView Earnings Details
5/2/2017Q1 2017$0.8150$0.79$3.6882 billion$3.6973 billionViewListenView Earnings Details
2/16/2017Q4 2016$0.91$0.98$3.74 billion$3.7157 billionViewListenView Earnings Details
11/2/2016Q316$0.94$0.95$3.72 billion$3.73 billionViewListenView Earnings Details
8/8/2016Q216$0.98$1.01$3.67 billion$3.72 billionViewListenView Earnings Details
5/4/2016Q116$0.86$0.92$3.51 billion$3.58 billionViewListenView Earnings Details
2/11/2016Q415$0.97$1.01$3.50 billion$3.5336 billionViewListenView Earnings Details
11/3/2015Q315$0.97$1.00$3.46 billion$3.5257 billionViewListenView Earnings Details
8/4/2015Q215$0.95$0.95$3.37 billion$3.4346 billionViewListenView Earnings Details
5/4/2015Q115$0.86$0.86$3.25 billion$3.2880 billionViewListenView Earnings Details
2/12/2015Q414$0.89$0.96$3.26 billion$3.3280 billionViewListenView Earnings Details
11/6/2014Q314$0.91$0.90$3.19 billion$3.2518 billionViewListenView Earnings Details
7/31/2014Q214$0.88$0.95$3.10 billion$3.1725 billionViewListenView Earnings Details
5/1/2014Q1$0.87$0.85$3.0230 billion$3.0428 billionViewListenView Earnings Details
2/11/2014Q413$1.91$0.99$2.92 billion$3.06 billionViewListenView Earnings Details
11/5/2013Q313$0.96$0.98$2.93 billion$2.9996 billionViewListenView Earnings Details
8/6/2013Q2 2013$1.84$1.84$2.88 billion$2.8717 billionViewListenView Earnings Details
5/7/2013Q1 2013$1.80$1.84$2.78 billion$2.8296 billionViewListenView Earnings Details
2/14/2013Q4 2012$1.60$1.85$2.40 billion$2.48 billionViewListenView Earnings Details
10/30/2012$1.55$1.56ViewN/AView Earnings Details
8/1/2012$1.47$1.49ViewN/AView Earnings Details
5/1/2012Q1 2012$0.73$0.73ViewN/AView Earnings Details
2/16/2012$1.49$1.58ViewN/AView Earnings Details
11/3/2011$1.46$1.45ViewN/AView Earnings Details
8/3/2011$1.14$1.17ViewN/AView Earnings Details
5/2/2011$0.95$0.96ViewN/AView Earnings Details
2/10/2011$1.12$0.70ViewN/AView Earnings Details
11/4/2010Q3 2010$0.57$0.57ViewN/AView Earnings Details
8/2/2010Q2 2010$0.54$0.53ViewN/AView Earnings Details
4/27/2010Q1 2010$0.52$0.52ViewN/AView Earnings Details
2/10/2010Q4 2009$0.53$0.53ViewN/AView Earnings Details
11/3/2009Q3 2009$0.50$0.53ViewN/AView Earnings Details
8/4/2009Q2 2009$0.48$0.51ViewN/AView Earnings Details
4/27/2009Q1 2009$0.45$0.46ViewN/AView Earnings Details
2/10/2009Q4 2008$0.45$0.47ViewN/AView Earnings Details
11/3/2008Q3 2008$0.44$0.44ViewN/AView Earnings Details
8/4/2008Q2 2008$0.42$0.45ViewN/AView Earnings Details
4/29/2008Q1 2008$0.39$0.40ViewN/AView Earnings Details
2/13/2008Q4 2007$0.40$0.40ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

DaVita (NYSE:DVA) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

DaVita (NYSE DVA) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 0.95%
Institutional Ownership Percentage: 87.62%
Insider Trading History for DaVita (NYSE:DVA)
Institutional Ownership by Quarter for DaVita (NYSE:DVA)

DaVita (NYSE DVA) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/14/2018Charles BergDirectorSell338$66.25$22,392.5029,776View SEC Filing  
1/16/2018James K HilgerInsiderSell3,572$78.95$282,009.4033,649View SEC Filing  
12/11/2017Charles BergInsiderSell7,048$69.24$488,003.525,359View SEC Filing  
12/8/2017Kent J ThiryChairmanSell81,800$68.04$5,565,672.00View SEC Filing  
12/8/2017Leanne M ZumwaltVPSell949$68.19$64,712.3112,423View SEC Filing  
12/7/2017James K HilgerInsiderSell5,608$69.46$389,531.6847,649View SEC Filing  
12/7/2017Javier RodriguezCEOSell22,532$67.48$1,520,459.36210,317View SEC Filing  
5/15/2017Javier RodriguezCEOSell1,294$66.21$85,675.7499,111View SEC Filing  
5/9/2017Charles BergDirectorSell8,414$65.80$553,641.2034,719View SEC Filing  
5/4/2017William L RoperDirectorSell12,994$65.89$856,174.6645,277View SEC Filing  
8/9/2016Michael David StaffieriCOOSell20,262$73.09$1,480,949.5852,279View SEC Filing  
7/11/2016Jeanine Marie JigantiInsiderSell1,291$78.51$101,356.415,716View SEC Filing  
7/1/2016Jeanine Marie JigantiInsiderSell4,620$77.45$357,819.007,590View SEC Filing  
5/25/2016Pamela M ArwayDirectorSell10,824$77.16$835,179.8436,394View SEC Filing  
5/23/2016James K HilgerCFOSell3,416$76.79$262,314.6429,147View SEC Filing  
5/20/2016Kent J ThiryCEOSell32,880$76.99$2,531,431.2039,184View SEC Filing  
5/17/2016Dennis KogodCEOSell17,700$77.35$1,369,095.0018,766View SEC Filing  
5/17/2016Leanne M ZumwaltVPSell538$77.08$41,469.048,585View SEC Filing  
5/16/2016James K HilgerCFOSell3,983$75.59$301,074.9721,130View SEC Filing  
5/16/2016Javier RodriguezCEOSell36,466$75.44$2,750,995.0464,264View SEC Filing  
5/16/2016Michael David StaffieriCOOSell4,934$75.69$373,454.4612,279View SEC Filing  
5/12/2016Roger ValineDirectorSell8,220$76.34$627,514.8018,324View SEC Filing  
5/10/2016Dennis KogodCEOSell40,048$76.25$3,053,660.0092,716View SEC Filing  
5/6/2016John M NehraDirectorSell16,314$75.56$1,232,685.8436,665View SEC Filing  
4/11/2016Javier RodriguezCEOSell89,912$73.51$6,609,431.12317,397View SEC Filing  
3/21/2016Dennis KogodCEOSell13,455$72.12$970,374.6092,716View SEC Filing  
2/29/2016Pamela M ArwayDirectorSell9,026$66.00$595,716.0036,070View SEC Filing  
2/23/2016Leanne M. ZumwaltVPSell14,587$64.25$937,214.75View SEC Filing  
2/16/2016Dennis KogodCEOSell33,290$61.99$2,063,647.10120,816View SEC Filing  
1/13/2016Christopher James SchnarrInsiderBuy5,000$0.68$3,400.00
1/11/2016Christopher James SchnarrInsiderBuy10,000$0.60$6,000.00
12/17/2015Laura MildenbergerinsiderSell1,440$68.14$98,121.608,447View SEC Filing  
9/22/2015Kim M. RiverainsiderSell40,037$75.48$3,021,992.767,438View SEC Filing  
8/17/2015Carol Anthony DavidsonDirectorSell4,038$79.93$322,757.34View SEC Filing  
6/4/2015Robert J MargolisChairmanSell31,400$83.39$2,618,446.00View SEC Filing  
5/28/2015Michael David StaffieriCOOSell9,050$84.07$760,833.50View SEC Filing  
5/19/2015Robert J MargolisChairmanSell15,700$83.22$1,306,554.00View SEC Filing  
5/18/2015James K HilgerCFOSell3,983$82.10$327,004.30View SEC Filing  
5/18/2015Michael David StaffieriCOOSell2,047$82.03$167,915.41View SEC Filing  
5/18/2015Robert J MargolisChairmanSell15,700$82.24$1,291,168.00View SEC Filing  
5/11/2015James K HilgerCFOSell8,267$82.00$677,894.00View SEC Filing  
5/11/2015Jeanine Marie JigantiInsiderSell2,481$81.95$203,317.95View SEC Filing  
5/11/2015John M NehraDirectorSell12,278$81.85$1,004,954.30View SEC Filing  
4/21/2015Robert J MargolisChairmanSell31,400$82.40$2,587,360.00View SEC Filing  
4/7/2015Robert J MargolisChairmanSell15,700$82.15$1,289,755.00View SEC Filing  
4/6/2015Robert J MargolisChairmanSell15,700$81.49$1,279,393.00View SEC Filing  
3/27/2015Robert J MargolisChairmanSell31,400$81.18$2,549,052.00View SEC Filing  
3/12/2015Robert J MargolisChairmanSell107,374$79.24$8,508,315.76View SEC Filing  
2/27/2015Robert J MargolisChairmanSell21,000$74.29$1,560,090.00View SEC Filing  
2/19/2015Robert J MargolisChairmanSell21,000$73.12$1,535,520.00View SEC Filing  
1/30/2015Robert J MargolisChairmanSell31,400$75.48$2,370,072.00View SEC Filing  
1/23/2015Michael David StaffieriCOOSell21,869$76.05$1,663,137.45View SEC Filing  
1/16/2015Robert J MargolisChairmanSell31,400$74.92$2,352,488.00View SEC Filing  
1/8/2015Kim M RiveraInsiderSell1,111$75.10$83,436.10View SEC Filing  
12/30/2014Robert J MargolisChairmanSell31,400$76.09$2,389,226.00View SEC Filing  
12/29/2014Robert J MargolisChairmanSell15,700$76.09$1,194,613.00View SEC Filing  
12/19/2014Laura MildenbergerInsiderSell1,446$75.50$109,173.00View SEC Filing  
12/18/2014Robert J MargolisChairmanSell31,400$74.67$2,344,638.00View SEC Filing  
12/3/2014Robert J MargolisChairmanSell31,400$75.80$2,380,120.00View SEC Filing  
12/1/2014Kim M RiveraInsiderSell6,503$76.08$494,748.24View SEC Filing  
11/21/2014Robert J MargolisChairmanSell31,400$75.08$2,357,512.00View SEC Filing  
11/11/2014Kent J ThiryCEOSell344,938$74.52$25,704,779.76View SEC Filing  
11/11/2014Robert J MargolisChairmanSell250,000$75.09$18,772,500.00View SEC Filing  
11/10/2014Berkshire Hathaway IncMajor ShareholderBuy944,418$74.11$69,990,817.98View SEC Filing  
11/7/2014R. Ted WeschlerMajor ShareholderBuy820,018$74.10$60,763,333.80View SEC Filing  
11/3/2014Roger ValineDirectorSell7,185$77.85$559,352.25View SEC Filing  
9/16/2014John M NehraDirectorSell20,000$73.91$1,478,200.00View SEC Filing  
9/8/2014Kim M RiveraInsiderSell1,111$74.25$82,491.75View SEC Filing  
8/27/2014Leanne M ZumwaltVPSell3,214$74.57$239,667.98View SEC Filing  
8/11/2014Jeanine Marie JigantiInsiderSell2,500$72.14$180,350.00View SEC Filing  
6/11/2014Kim M RiveraInsiderSell5,929$71.05$421,255.45View SEC Filing  
5/29/2014Laura MildenbergerInsiderSell5,080$69.99$355,549.20View SEC Filing  
5/16/2014Dennis KogodCOOSell18,750$67.30$1,261,875.0040,874View SEC Filing  
5/16/2014Kent ThiryCEOSell17,600$67.41$1,186,416.00247,950View SEC Filing  
5/15/2014James HilgerCAOSell1,666$67.23$112,005.1813,277View SEC Filing  
5/15/2014Javier RodriguezCEOSell7,000$67.50$472,500.0064,264View SEC Filing  
5/12/2014Dennis KogodCOOSell32,188$68.06$2,190,715.2859,624View SEC Filing  
5/8/2014Dennis KogodCOOSell32,213$67.36$2,169,867.6859,624View SEC Filing  
5/7/2014Michael David StaffieriCOOSell2,633$67.30$177,200.90View SEC Filing  
4/2/2014Michael David StaffieriCOOSell2,867$69.15$198,253.052,633View SEC Filing  
3/20/2014Laura MildenbergerInsiderSell3,274$70.04$229,310.966,036View SEC Filing  
2/26/2014R. Ted Weschlermajor shareholderBuy1,159,858$66.97$77,675,690.262,191,806View SEC Filing  
2/21/2014John NehraDirectorSell40,000$65.81$2,632,400.0081,766View SEC Filing  
2/18/2014William RoperDirectorSell42,519$66.37$2,821,986.034,994View SEC Filing  
12/20/2013Laura MildenbergerInsiderSell10,417$62.53$651,375.016,036View SEC Filing  
12/17/2013Allen NissensonInsiderSell2,929$59.83$175,242.072,508View SEC Filing  
12/9/2013Berkshire Hathaway Incmajor shareholderBuy1,314,170$57.84$76,011,592.80View SEC Filing  
11/8/2013R. Ted Weschlermajor shareholderBuy3,700,294$55.14$204,034,211.161,095,903View SEC Filing  
7/5/2013Berkshire Hathaway IncMajor ShareholderBuy110,309$114.01$12,576,329.09View SEC Filing  
7/3/2013R. Ted WeschlerMajor ShareholderBuy639,200$114.78$73,367,376.00View SEC Filing  
5/15/2013David T ShapiroInsiderSell8,779$129.80$1,139,514.20View SEC Filing  
5/15/2013Dennis KogodCOOSell21,130$129.47$2,735,701.10View SEC Filing  
5/15/2013James K HilgerCFOSell1,049$130.18$136,558.82View SEC Filing  
5/15/2013Leanne M ZumwaltVPSell13,209$129.59$1,711,754.31View SEC Filing  
5/13/2013Kent J ThiryCEOSell243,307$129.95$31,617,744.65View SEC Filing  
5/13/2013Kim M RiveraInsiderSell1,672$129.70$216,858.40View SEC Filing  
3/4/2013Berkshire Hathaway IncMajor ShareholderBuy164,947$119.59$19,726,011.73View SEC Filing  
3/4/2013Roger ValineDirectorSell1,390$120.00$166,800.00View SEC Filing  
2/27/2013Berkshire Hathaway IncMajor ShareholderBuy211,889$116.56$24,697,781.84View SEC Filing  
2/22/2013Berkshire Hathaway IncMajor ShareholderBuy224,091$115.88$25,967,665.08View SEC Filing  
2/19/2013Berkshire Hathaway IncMajor ShareholderBuy323,070$116.73$37,711,961.10View SEC Filing  
2/5/2013Berkshire Hathaway IncMajor ShareholderBuy32,376$115.17$3,728,743.92View SEC Filing  
2/4/2013Roger ValineDirectorSell1,389$116.13$161,304.57View SEC Filing  
1/16/2013Berkshire Hathaway IncMajor ShareholderBuy42,400$111.33$4,720,392.00View SEC Filing  
1/15/2013Berkshire Hathaway IncMajor ShareholderBuy179,300$109.67$19,663,831.00View SEC Filing  
1/10/2013Berkshire Hathaway IncMajor ShareholderBuy187,898$109.54$20,582,346.92View SEC Filing  
12/24/2012Dennis KogodCOOSell12,736$111.00$1,413,696.00View SEC Filing  
12/21/2012James K HilgerCFOSell2,073$112.20$232,590.60View SEC Filing  
12/6/2012Berkshire Hathaway IncMajor ShareholderBuy635,633$106.20$67,504,224.60View SEC Filing  
11/29/2012Berkshire Hathaway IncMajor ShareholderBuy679,249$108.20$73,494,741.80View SEC Filing  
11/26/2012Berkshire Hathaway IncMajor ShareholderBuy412,050$110.38$45,482,079.00View SEC Filing  
11/16/2012Berkshire Hathaway IncMajor ShareholderBuy132,958$112.45$14,951,127.10View SEC Filing  
11/12/2012Berkshire Hathaway IncMajor ShareholderBuy548,823$112.15$61,550,499.45View SEC Filing  
11/7/2012Berkshire Hathaway IncMajor ShareholderBuy139,491$112.03$15,627,176.73View SEC Filing  
11/2/2012Berkshire Hathaway IncMajor ShareholderBuy254,750$112.20$28,582,950.00View SEC Filing  
10/26/2012Berkshire Hathaway IncMajor ShareholderBuy257,941$111.14$28,667,562.74View SEC Filing  
10/17/2012Berkshire Hathaway IncMajor ShareholderBuy63,928$109.56$7,003,951.68View SEC Filing  
10/12/2012Berkshire Hathaway IncMajor ShareholderBuy217,597$109.76$23,883,446.72View SEC Filing  
10/9/2012Berkshire Hathaway IncMajor ShareholderBuy67,946$107.71$7,318,463.66View SEC Filing  
9/28/2012Berkshire Hathaway IncMajor ShareholderBuy282,403$102.03$28,813,578.09View SEC Filing  
8/8/2012Kent J ThiryChairmanSell320,877$96.88$31,086,563.76View SEC Filing  
8/7/2012William L RoperDirectorSell23,019$95.95$2,208,673.05View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

DaVita (NYSE DVA) News Headlines

Source:
DateHeadline
Form 4 DAVITA INC. For: May 15 Filed by: HEARTY JAMES OForm 4 DAVITA INC. For: May 15 Filed by: HEARTY JAMES O
www.streetinsider.com - May 18 at 6:05 PM
Form 4 DAVITA INC. For: May 15 Filed by: ACKERMAN JOELForm 4 DAVITA INC. For: May 15 Filed by: ACKERMAN JOEL
www.streetinsider.com - May 18 at 6:05 PM
Form 4 DAVITA INC. For: May 15 Filed by: DIAZ PAUL JForm 4 DAVITA INC. For: May 15 Filed by: DIAZ PAUL J
www.streetinsider.com - May 18 at 8:29 AM
Form 4 DAVITA INC. For: May 15 Filed by: YALE PHYLLIS RForm 4 DAVITA INC. For: May 15 Filed by: YALE PHYLLIS R
www.streetinsider.com - May 18 at 8:29 AM
DaVita (DVA) Expected to Post Earnings of $0.98 Per ShareDaVita (DVA) Expected to Post Earnings of $0.98 Per Share
www.americanbankingnews.com - May 17 at 7:28 PM
Form 4 DAVITA INC. For: May 14 Filed by: BERG CHARLESForm 4 DAVITA INC. For: May 14 Filed by: BERG CHARLES
www.streetinsider.com - May 17 at 8:18 AM
DaVita (DVA) Director Sells $22,392.50 in StockDaVita (DVA) Director Sells $22,392.50 in Stock
www.americanbankingnews.com - May 16 at 10:28 PM
DaVita Teammates Volunteer with Bridge of Life and the Syrian American Medical Society to Support Health Care ...DaVita Teammates Volunteer with Bridge of Life and the Syrian American Medical Society to Support Health Care ...
www.prnewswire.com - May 16 at 8:15 AM
Complimentary Breakfast Technical Briefing on DaVita and Three Specialized Health Services StocksComplimentary Breakfast Technical Briefing on DaVita and Three Specialized Health Services Stocks
finance.yahoo.com - May 16 at 8:15 AM
DaVita Teammates Volunteer with Bridge of Life and the Syrian American Medical Society to Support Health Care Needs of Syrian Refugees in JordanDaVita Teammates Volunteer with Bridge of Life and the Syrian American Medical Society to Support Health Care Needs of Syrian Refugees in Jordan
finance.yahoo.com - May 16 at 8:15 AM
DaVita Sees Unusually High Options Volume (DVA)DaVita Sees Unusually High Options Volume (DVA)
www.americanbankingnews.com - May 16 at 6:36 AM
Critical Analysis: Catasys (CATS) vs. DaVita (DVA)Critical Analysis: Catasys (CATS) vs. DaVita (DVA)
www.americanbankingnews.com - May 15 at 11:16 PM
Contrasting DaVita (DVA) and Catasys (CATS)Contrasting DaVita (DVA) and Catasys (CATS)
www.americanbankingnews.com - May 15 at 3:08 AM
Comparing Caladrius Biosciences (CLBS) & DaVita (DVA)Comparing Caladrius Biosciences (CLBS) & DaVita (DVA)
www.americanbankingnews.com - May 13 at 11:16 PM
DaVita (DVA) versus Caladrius Biosciences (CLBS) Financial ComparisonDaVita (DVA) versus Caladrius Biosciences (CLBS) Financial Comparison
www.americanbankingnews.com - May 12 at 1:25 PM
BRIEF-Berkshire Hathaway Inc Reports 22.1 Percent Stake In Davita Inc As Of May 3, 2018BRIEF-Berkshire Hathaway Inc Reports 22.1 Percent Stake In Davita Inc As Of May 3, 2018
www.reuters.com - May 11 at 6:02 PM
Form 4 DAVITA INC. For: May 06 Filed by: Waters Kathleen AlyceForm 4 DAVITA INC. For: May 06 Filed by: Waters Kathleen Alyce
www.streetinsider.com - May 9 at 5:38 PM
DaVita Endorses International Initiative Aimed at Helping Give Patients a Voice in Kidney Care Trials and ResearchDaVita Endorses International Initiative Aimed at Helping Give Patients a Voice in Kidney Care Trials and Research
finance.yahoo.com - May 8 at 8:13 AM
RN, Case Manager, Per DiemRN, Case Manager, Per Diem
www.bizjournals.com - May 7 at 8:16 AM
Health Care Heroes: DaVita Celebrates its Kidney Care Nurses During National Nurses WeekHealth Care Heroes: DaVita Celebrates its Kidney Care Nurses During National Nurses Week
finance.yahoo.com - May 7 at 8:16 AM
William Blair Brokers Raise Earnings Estimates for Davita Inc (DVA)William Blair Brokers Raise Earnings Estimates for Davita Inc (DVA)
www.americanbankingnews.com - May 7 at 2:28 AM
Davita Inc (DVA) Given Average Recommendation of "Hold" by BrokeragesDavita Inc (DVA) Given Average Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - May 7 at 1:40 AM
RN, Care ManagerRN, Care Manager
www.bizjournals.com - May 6 at 7:45 PM
Davita (DVA) Issues Quarterly  Earnings ResultsDavita (DVA) Issues Quarterly Earnings Results
www.americanbankingnews.com - May 5 at 12:46 AM
DaVita (DVA) Q1 2018 Results - Earnings Call TranscriptDaVita (DVA) Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 4 at 8:16 AM
Edited Transcript of DVA earnings conference call or presentation 3-May-18 9:00pm GMTEdited Transcript of DVA earnings conference call or presentation 3-May-18 9:00pm GMT
finance.yahoo.com - May 4 at 8:16 AM
BRIEF-DaVita Reports Q1 Earnings Per Share $1.05 From Continuing OperationsBRIEF-DaVita Reports Q1 Earnings Per Share $1.05 From Continuing Operations
www.reuters.com - May 3 at 5:29 PM
DaVita HealthCare Partners Inc. Q1 adjusted earnings of $1.05 per shareDaVita HealthCare Partners Inc. Q1 adjusted earnings of $1.05 per share
www.nasdaq.com - May 3 at 5:29 PM
DaVita HealthCare: 1Q Earnings SnapshotDaVita HealthCare: 1Q Earnings Snapshot
finance.yahoo.com - May 3 at 5:29 PM
DaVita Inc. 1st Quarter 2018 ResultsDaVita Inc. 1st Quarter 2018 Results
finance.yahoo.com - May 3 at 5:29 PM
DaVitas Sustainability Efforts Rewarded by Department of EnergyDaVita's Sustainability Efforts Rewarded by Department of Energy
finance.yahoo.com - May 2 at 5:39 PM
Head to Head Comparison: Tivity Health (TVTY) and Davita (DVA)Head to Head Comparison: Tivity Health (TVTY) and Davita (DVA)
www.americanbankingnews.com - May 2 at 3:24 PM
Zacks: Brokerages Anticipate Davita Inc (DVA) Will Announce Quarterly Sales of $2.96 BillionZacks: Brokerages Anticipate Davita Inc (DVA) Will Announce Quarterly Sales of $2.96 Billion
www.americanbankingnews.com - May 2 at 4:32 AM
Davita Inc (DVA) Expected to Announce Earnings of $0.92 Per ShareDavita Inc (DVA) Expected to Announce Earnings of $0.92 Per Share
www.americanbankingnews.com - April 30 at 7:33 AM
Davita (DVA) & Caladrius Biosciences (CLBS) Head to Head SurveyDavita (DVA) & Caladrius Biosciences (CLBS) Head to Head Survey
www.americanbankingnews.com - April 29 at 9:20 AM
Critical Analysis: Davita (DVA) vs. Tivity Health (TVTY)Critical Analysis: Davita (DVA) vs. Tivity Health (TVTY)
www.americanbankingnews.com - April 29 at 1:18 AM
BRIEF-DaVita Says CEO Kent Thirys Total 2017 Compensation Was $15.3 MlnBRIEF-DaVita Says CEO Kent Thiry's Total 2017 Compensation Was $15.3 Mln
www.reuters.com - April 28 at 8:24 AM
Methodist launching data-sharing program to keep transplant candidates ready to receiveMethodist launching data-sharing program to keep transplant candidates ready to receive
finance.yahoo.com - April 27 at 5:17 PM
Global Dialysis Market 2018 Forecast to 2022 - Key Players are Fresenius Medical Care, DaVita, Baxter and B. Braun ...Global Dialysis Market 2018 Forecast to 2022 - Key Players are Fresenius Medical Care, DaVita, Baxter and B. Braun ...
www.businesswire.com - April 27 at 8:26 AM
DaVita Continues to Improve Patient Care, Leads in Five-Star Quality RatingsDaVita Continues to Improve Patient Care, Leads in Five-Star Quality Ratings
finance.yahoo.com - April 27 at 8:26 AM
Davita Target of Unusually Large Options Trading (DVA)Davita Target of Unusually Large Options Trading (DVA)
www.americanbankingnews.com - April 26 at 7:14 AM
Davita (DVA) Set to Announce Quarterly Earnings on ThursdayDavita (DVA) Set to Announce Quarterly Earnings on Thursday
www.americanbankingnews.com - April 26 at 1:40 AM
How Highmark and a provider are working to lower the cost of dialysis careHow Highmark and a provider are working to lower the cost of dialysis care
finance.yahoo.com - April 24 at 5:38 PM
DaVita and Methodist Specialty and Transplant Hospital Collaborate to Launch Technology Designed to Help Improve ...DaVita and Methodist Specialty and Transplant Hospital Collaborate to Launch Technology Designed to Help Improve ...
www.prnewswire.com - April 24 at 8:16 AM
DaVita and Methodist Specialty and Transplant Hospital Collaborate to Launch Technology Designed to Help Improve Transplant Readiness of PatientsDaVita and Methodist Specialty and Transplant Hospital Collaborate to Launch Technology Designed to Help Improve Transplant Readiness of Patients
finance.yahoo.com - April 24 at 8:16 AM
DaVita Recognized as a LearningElite Company by Chief Learning Officer MagazineDaVita Recognized as a LearningElite Company by Chief Learning Officer Magazine
finance.yahoo.com - April 23 at 5:16 PM
DaVita Releases 10th Annual Community Care ReportDaVita Releases 10th Annual Community Care Report
finance.yahoo.com - April 19 at 8:12 AM
Buying Binge For UnitedHealths Optum Is Only Just BeginningBuying Binge For UnitedHealth's Optum Is Only Just Beginning
finance.yahoo.com - April 18 at 8:12 AM
Williamsville dialysis center plans new siteWilliamsville dialysis center plans new site
www.bizjournals.com - April 17 at 6:00 PM
ION Announces Executive Vice President, Corporate Compliance OfficerION Announces Executive Vice President, Corporate Compliance Officer
www.prnewswire.com - April 17 at 8:24 AM

SEC Filings

DaVita (NYSE:DVA) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

DaVita (NYSE:DVA) Income Statement, Balance Sheet and Cash Flow Statement

Chart

DaVita (NYSE DVA) Stock Chart for Monday, May, 21, 2018

Loading chart…

This page was last updated on 5/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.